TITLE

Delays to reperfusion therapy in acute ST-segment elevation myocardial infarction: results from the AMI-QUEBEC Study

AUTHOR(S)
Thao Huynh; O'Loughlin, Jennifer; Joseph, Lawrence; Schampaert, Erick; Rinfret, Stéphane; Afilalo, Marc; Kouz, Simon; Cantin, Bernard; Nguyen, Michel; Eisenberg, Mark J.
PUB. DATE
December 2006
SOURCE
CMAJ: Canadian Medical Association Journal;12/5/2006, Vol. 175 Issue 12, p1527
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Background: Through the AMI-QUEBEC Study we sought to describe delays to reperfusion therapy for ST-segment elevation myocardial infarction (STEMI) and to identify factors associated with prolonged delays. Methods: We reviewed the charts of all consecutive patients with STEMI admitted to 17 hospitals in the province of Quebec in 2003 to obtain data on the time from presentation to reperfusion therapy. Data were available for 1189 (83.0%) of 1432 patients. Results: The median delay to reperfusion therapy was 32 minutes (first and third quartile [Q1, Q3] 20, 49) for 535 patients who received fibrinolytic therapy, 109 minutes (Q1, Q3 79, 150) for 455 patients who underwent primary percutaneous coronary intervention (PCI) at the initial hospital of presentation and 142 minutes (Q1, Q3 115, 194) for 199 patients who underwent primary PCI after an interhospital transfer. Patients who presented outside daytime working hours, those who received primary PCI and those who required interhospital transfer for primary PCI were less likely to receive reperfusion therapy within current recommended times (odds ratios [ORs] 0.49, 0.56 and 0.15, respectively). Increased age was associated with prolonged delays only among patients who received fibrinolytic therapy (OR for each 10-year increase in age 0.95, 95% credible interval [CrI] 0.93-0.99 for fibrinolytic therapy and 0.99, 95% CrI 0.95-1.05, for primary PCI). Interpretation: In 2003, many patients with STEMI in Quebec were not treated within the recommended times. Delays may be reduced by reorganizing pre- and in-hospital care for patients with STEMI to expedite delivery of reperfusion therapy.
ACCESSION #
23229449

 

Related Articles

  • Low frequency mechanical actuation accelerates reperfusion in-vitro. Marzencki, Marcin; Kajbafzadeh, Behrad; Khosrow-khavar, Farzad; Tavakolian, Kouhyar; Soleimani-Nouri, Maxim; Hamburger, Jaap; Kaminska, Bozena; Menon, Carlo // BioMedical Engineering OnLine;2013, Vol. 12 Issue 1, p2 

    Background Rapid restoration of vessel patency after acute myocardial infarction is key to reducing myocardial muscle death and increases survival rates. Standard therapies include thrombolysis and direct PTCA. Alternative or adjunctive emergency therapies that could be initiated by minimally...

  • FACTORS INFLUENCING OUTCOME IN LEFT VENTRICULAR FUNCTION FOLLOWING RESCUE PERCUTANEOUS CORONARY INTERVENTION. Balachandran, K. P.; Berry, C.; Gilbert, T. J.; Malekian, M.; Pell, A. C. H.; Vallance, B. D.; Oldroyd, K. G. // Heart;May2004 Supplement 3, Vol. 90, pA7 

    The article presents factors influencing outcome in left ventricular function following rescue percutaneous coronary intervention (PCI). Many patients do not achieve complete reperfusion following thrombolytic therapy for acute myocardial infarction (AMI). For this reason, some centres in Great...

  • Reperfusion strategy for acute myocardial infarction in elderly patients aged 75 to 80 years. Watanabe, Ikuyoshi; Nagao, Ken; Tani, Shigemasa; Masuda, Naoki; Yahata, Takaharu; Ohguchi, Sumito; Kanmatsuse, Katsuo; Kushiro, Toshio // Heart & Vessels;Jul2006, Vol. 21 Issue 4, p236 

    The increasing elderly population will influence the treatment policies adopted in cases of acute myocardial infarction. Considering reperfusion therapy in elderly patients with acute myocardial infarction, we compared three strategies, as follows: primary percutaneous coronary intervention...

  • Recent advances in primary percutaneous intervention for acute myocardial infarction. Smith, E. J.; Mathur, A.; Rothman, M. T. // Heart;Dec2005, Vol. 91 Issue 12, p1533 

    The article presents a discussion on the recent advances in primary percutaneous intervention (PPCI) for acute myocardial infarction (AMI). Interventional cardiology has evolved since the first studies comparing PPCI and intravenous thrombolysis for the treatment of ST segment elevation...

  • Myocardial Ischaemia-Reperfusion Syndrome. ALDANA BITAR, JAIRO ALEJANDRO; PACHECO, DAVID SANTACRUZ; URINA TRIANA, MANUEL ELISEO // Universitas Médica;abr-jun2014, Vol. 55 Issue 2, p166 

    Reperfusion is the definitive treatment to salvage ischemic myocardium from infarction. A primary determinant of infarct size is the duration of ischemia. Early reestablishment of blood flow to ischaemic myocardium limits infarct size and reduces mortality. In a paradoxical manner, the return of...

  • Systemic Inflammation and Reperfusion Injury in Patients With Acute Myocardial Infarction. Blancke, Fien; Claeys, Marc J.; Jorens, Philippe; Vermeiren, Guy; Bosmans, Johan; Wuyts, Floris L.; Vrints, Chris J. // Mediators of Inflammation;12/14/2005, Vol. 2005 Issue 6, p385 

    Despite early recanalization of an occluded infarct artery, tissue reperfusion remains impaired in more than one-third of the acute myocardial infarction (AMI) patients owing to a process of reperfusion injury. The role of systemic inflammation in triggering this phenomenon is unknown....

  • INDIGENOUS RECOMBINANT STREPTOKINASE VS NATURAL STREPTOKINASE IN ACUTE MYOCARDIAL INFARCTION PATIENTS: PHASE III MULTICENTRIC RANDOMIZED DOUBLE BLIND TRIAL. Diwedi, S. K.; Hiremath, J. S.; Kerkar, P. G.; Reddy, Krishna N.; Manjunath, C. N.; Ramesh, S. S.; Prabhavati, S.; Dhobe, M.; Singh, Kavita; Bhusari, P.; Rao, Raman // Indian Journal of Medical Sciences;May2005, Vol. 59 Issue 5, p200 

    BACKGROUND: Streptokinase is the most widely used thrombolytic agent and can now be made using recombinant DNA technology. The present trial was initiated to assess an indigenous recombinant streptokinase (Shankinase, r-SK). AIM: To compare the efficacy and safety of indigenous recombinant...

  • "No-Reflow" Phenomenon Following Percutaneous Coronary Intervention: An Uncommon Complication. Safi, Arshad M.; Kwan, Tak W. // Angiology;Mar2000, Vol. 51 Issue 3, p247 

    The no-reflow phenomenon has been recognized as an uncommon complication after reperfusion therapy (thrombolytic or mechanical) for acute myocardial infarction and after percutaneous coronary intervention. As management and outcomes differ, early diagnosis and angiographic exclusion of other...

  • Effect of postconditioning on infarct size in patients with ST elevation myocardial infarction. Sörensson, Peder; Saleh, Nawzad; Bouvier, Frederic; Böhm, Felix; Settergren, Magnus; Caidahl, Kenneth; Tornvall, Per; Arheden, Håkan; Rydèc)n, Lars; Pernow, John // Heart;Nov2010, Vol. 96 Issue 21, p1710 

    Background Small studies suggest that postconditioning reperfusion interrupted by brief repetitive cycles of reocclusions, may protect the myocardium in the clinical setting. Objective To test the hypothesis that postconditioning limits infarct size in relation to the area at risk in patients...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics